ArticleTargeted oncology2025
Population Exposure-Response Efficacy Analysis of Elranatamab (PF-06863135) in Patients with Multiple Myeloma.
Article in Targeted oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Magnetismm-1 a phase i, open label study to evaluate the safety, pharmacokinetic, pharmacodynamic and clinical activity of elranatamab (pf-06863135), a b-cell maturation antigen (bcma) - cd3 bispecific antibody, as a single agent and in combination with immunomodulatory agents in patients with relapsed/refractory advanced multiple myeloma (mm)
Magnetismm-3 an open-label, multicenter, non-randomized phase 2 study of elranatamab (pf-06863135) monotherapy in participants with multiple myeloma who are refractory to at least one proteasome inhibitor, one immunomodulatory drug and one anti-cd38 antibody
A phase i, open label study to evaluate the safety and pharmacokinetic of pf 06863135, a b cell maturation antigen (bcma) cd3 bispecific antibody, as a single agent in japanese participants with relapsed/refractory advanced multiple myeloma
A phase 1/2, open-label, multicenter study to evaluate a dosing regimen with two step-up priming doses and longer dosing intervals of elranatamab (pf-06863135) monotherapy in participants with relapsed/refractory multiple myeloma
Who cites it
5 citing papers in PubMed.
- Spatial transcriptomics identifies a suppressive, T-cell-excluded tumor microenvironment in extramedullary myeloma.Blood advances · 2026Article
- Elranatamab Population Pharmacokinetics and Exposure-Response for Cytokine Release Syndrome in Patients with Relapsed or Refractory Multiple Myeloma.Clinical pharmacokinetics · 2026Article
- Elranatamab: Mechanism of Action, Clinical, and Translational Science.Clinical and translational science · 2026Review
- Review
- Emerging precision medicine in multiple myeloma: clinical and preclinical landscape of T cell, natural killer cell, and macrophages engaging multi-specific antibodies.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundElranatamab is a heterodimeric humanized full-length bispecific antibody composed of one B-cell maturation antigen (BCMA) binding arm and one cluster of differentiation 3 (CD3) binding arm. Results from the MagnetisMM-3 study indicated deep and durable responses in patients with relapsed or refractory multiple myeloma (RRMM).
objectiveThe current analysis was conducted to characterize the relationship between free (i.e., unbound) elranatamab exposure and objective response rate (ORR), complete response rate (CRR), progression-free survival (PFS), and duration of response (DOR), and the impact of potential covariates on these exposure-response (E-R) relationships. PATIENTS AND
methodsData from four clinical studies and a wide dosing range were used for the E-R analysis. The E-R analyses of ORR and CRR were conducted by binomial logistic regression method, whereas Kaplan-Meier (KM) curves and Cox proportional hazards (PH) model were used for PFS and DOR.
resultsThe analysis included data from 312 response-evaluable patients. The results suggested that higher elranatamab exposure and lower soluble BCMA (sBCMA) were associated with higher probability of achieving objective response (OR) and complete response (CR). For PFS, higher exposure was associated with longer PFS, which is driven by rapid responses or progression events within the initial treatment cycles. At later time points, a flat relationship between exposure and PFS was observed. No E-R relationship was identified for DOR.
conclusionsThe current analyses support the approved initial dosing regimen of elranatamab and the dosing switch to less frequent dosing in responding patients during later treatment cycles. CLINICALTRIALS: GOV IDENTIFIERS: NCT03269136, NCT04798586, NCT04649359, and NCT05014412.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.